Tysabri Revised RiskMAP Would Have Mandatory Patient/Physician Registry Enrollment

Biogen Idec’s revised risk management plan for its multiple sclerosis therapy Tysabri adopts most changes sought by FDA in a critique of the company’s original risk plan.